TGFB2 and glioblastoma: (3) Results: The GBM patients had high levels of TGFB2 gene methylation; this primarily benefited the young adult male patients, and multivariate analysis exhibited a significantly improved OS prognosis HR (95% CI range) = 0.04 (0.006–0.274); p = 0.001) relative to the TGFB1highMe (HR (95% CI range) = 0.657 (0.454–0.951); p = 0.026) and MGMThighMe (HR (95% CI range) = 0.667 (0.475–0.936); p = 0.019) groups of GBM patients.